Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 5,923 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Mouth Disease Clear all

Conditions: COVID-19 SARS-CoV-2 Infection
Interventions: ibuzatrelvir, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 2,330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 90
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Bakersfield, California + 66 more

Conditions: Head and Neck Cancer
Interventions: fluorouracil, gemcitabine hydrochloride, paclitaxel, radiation therapy; Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Abnormal Uterine Bleeding, Abnormal Uterine Bleeding, Ovulatory Dysfunction, Abnormal Uterine Bleeding, Endometrial Hemostatic Dysfunction
Interventions: Levonorgestrel intrauterine system, Combined oral contraceptives; Device · Drug
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years to 51 Years · Female only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Advanced Cervical Adenocarcinoma, Advanced Cervical Adenosquamous Carcinoma, Advanced Cervical Squamous Cell Carcinoma, Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma, Advanced Vaginal Squamous Cell Carcinoma, Stage IB2 Cervical Cancer AJCC v6 and v7, Stage II Cervical Cancer AJCC v7, Stage II Vaginal Cancer AJCC v6 and v7, Stage III Vaginal Cancer AJCC v6 and v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7, Stage IVA Vaginal Cancer AJCC v6 and v7
Interventions: Biospecimen Collection, Brachytherapy, Cisplatin, Computed Tomography, External Beam Radiation Therapy, Fludeoxyglucose F-18, High-Dose Rate Brachytherapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Pharmacological Study, Positron Emission Tomography, Triapine; Procedure · Radiation · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 17
States / cities: Birmingham, Alabama • Los Angeles, California • Pasadena, California + 13 more

Conditions: Endometriosis, Pelvic Pain
Interventions: Oral Contraceptive, Depot-Leuprolide/Norethindrone; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 52 Years · Female only
Enrollment: 194 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2004
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Plaque
Interventions: 0.454%Stannous fluoride toothpaste, 0.075% Cetylpyridinium Chloride (CPC) and 0.28% zinc lactatmouthwashe, 0.76% Sodium Monofluorophosphate (Na MFP) toothpaste, 0.022% Sodium Fluoride mouthwash; Drug
Lead sponsor: Colgate Palmolive; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 134 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Melbourne, Florida

Conditions: Orthopoxviral Disease
Interventions: ST-246 400 mg, ST-246 600 mg, Placebo; Drug
Lead sponsor: SIGA Technologies; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Santa Ana, California • Orlando, Florida • Honolulu, Hawaii

Conditions: Trigeminal Neuralgia
Interventions: Amifostine, CyberKnife stereotactic radiosurgery; Drug · Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Stanford, California

Conditions: HIV Infections
Interventions: Zidovudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 11
States / cities: Tucson, Arizona • Chicago, Illinois • Baltimore, Maryland + 6 more

Conditions: Schizophrenia
Interventions: Ziprasidone 80-160 mg/d, Placebo, Ziprasidone 160 mg/d; Drug
Lead sponsor: Donald C. Goff, MD; Other
Eligibility: 18 Years to 65 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 9
States / cities: Augusta, Georgia • Fall River, Massachusetts • Grand Rapids, Michigan + 6 more

Conditions: Musculoskeletal Pain
Interventions: Methylprednisolone 4Mg Tab, Acetaminophen 500Mg Tab, Ibuprofen 200Mg Oral Tablet; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Gingivitis
Interventions: Stannous Fluoride Dentifrice, Sodium Fluoride Dentifrice, electric toothbrush, Cetylpyridinium Chloride (CPC), manual toothbrush; Drug · Device
Lead sponsor: Procter and Gamble; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Oral Mucositis, Stomatitis
Interventions: velafermin, placebo; Drug
Lead sponsor: CuraGen Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 33
States / cities: Little Rock, Arkansas • Berkley, California • La Jolla, California + 26 more

Conditions: Glioblastoma Multiforme, Anaplastic Astrocytoma
Interventions: Erlotinib; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Gastrointestinal Stromal Tumors (GIST), Neoplasms, Connective Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type, Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasm, Digestive System Disease, Gastrointestinal Diseases
Interventions: THE-630; Drug
Lead sponsor: Theseus Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 7
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Miami, Florida + 4 more

Conditions: Lymphoma, T-Cell
Interventions: Durvalumab, Pralatrexate, Romidepsin, 5-Azacitidine; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Medical Oncology
Interventions: BAY1217389, Paclitaxel; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 6
States / cities: Santa Monica, California • Denver, Colorado • New Haven, Connecticut + 3 more

Conditions: Breast Cancer, Head and Neck Cancer, Lymphoma, Metastatic Cancer, Non-melanomatous Skin Cancer, Sarcoma
Interventions: silicon phthalocyanine 4; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Breast Cancer
Interventions: Calcitriol; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 88 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2021
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Atrial Fibrillation, Obesity, Anticoagulants
Interventions: Apixaban; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 107,383 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Lip and Oral Cavity Carcinoma, Metastatic Nasal Cavity Squamous Cell Carcinoma, Metastatic Nasopharyngeal Squamous Cell Carcinoma, Metastatic Pharyngeal Squamous Cell Carcinoma, Metastatic Sinonasal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Recurrent Pharyngeal Squamous Cell Carcinoma, Recurrent Sinonasal Squamous Cell Carcinoma, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8
Interventions: Atezolizumab, Bevacizumab, Biospecimen Collection, Carboplatin, Cetuximab, Cisplatin, Computed Tomography, Docetaxel, Echocardiography Test, Magnetic Resonance Imaging, Positron Emission Tomography; Biological · Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 172
States / cities: Little Rock, Arkansas • Dublin, California • Emeryville, California + 135 more

Conditions: Leukemia
Interventions: topotecan hydrochloride; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2006
U.S. locations: 35
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 27 more

Conditions: Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3, Squamous Lung Cancer With FGFR1 Amplification, Bladder Cancer With FGFR3 Mutation or Fusion, Advanced Solid Tumors With FGFR1 Amplication, Advanced Solid Tumors With FGFR2 Amplication, Advanced Solid Tumors With FGFR3 Mutation
Interventions: BGJ398; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 16
States / cities: Duarte, California • Los Angeles, California • Aurora, Colorado + 10 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Nintedanib; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 752 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 37
States / cities: Jasper, Alabama • Phoenix, Arizona • Los Angeles, California + 34 more

Search by objective public record fields.

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced and/or Recurrent Head and Neck Cancer

Stopping Heavy Periods Project

Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer

Medical Treatment of Endometriosis-Associated Pelvic Pain

Efficacy of a Stannous Fluoride Toothpaste, Cetylpyridinium Chloride Mouthwash, and Battery Toothbrush Regimen in Reducing Established Dental Plaque and Gingivitis.

Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246

A Study of Amifostine for Prevention of Facial Numbness in Radiosurgery Treatment of Trigeminal Neuralgia

A Dose-Frequency Trial of Oral Retrovir in Patients With AIDS or Severe ARC

High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms

Musculoskeletal Outcomes Using Tylenol/Ibuprofen vs. Oral Steroids in New Injuries

A Study is to Evaluate a Regimen on Gingivitis Using Traditional and Novel Assessment Methods

A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis

Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma

A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel

Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin

Effects of High Dose Calcitriol in Breast Cancer Patients

Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Chemotherapy in Treating Children With Relapsed Acute Leukemia, Acute Myeloid Leukemia, or Blastic Phase Chronic Myelogenous Leukemia

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis